Eraxis en es it fr

Eraxis Brand names, Eraxis Analogs

Eraxis Brand Names Mixture

  • No information avaliable

Eraxis Chemical_Formula


Eraxis RX_link

No information avaliable

Eraxis fda sheet

Eraxis FDA

Eraxis msds (material safety sheet)

Eraxis MSDS

Eraxis Synthesis Reference

No information avaliable

Eraxis Molecular Weight

584.726 g/mol

Eraxis Melting Point

No information avaliable

Eraxis H2O Solubility


Eraxis State


Eraxis LogP


Eraxis Dosage Forms

Capsules (250 mg)

Eraxis Indication

For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

Eraxis Pharmacology

Tipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Eraxis Absorption

Absorption is limited, although no absolute quantification of absorption is available.

Eraxis side effects and Toxicity

Oral LD50 in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

Eraxis Patient Information

No information avaliable

Eraxis Organisms Affected

Human immunodeficiency virus